Novartis

Novartis, a Pharmaceutical Preparation Manufacturing company headquartered in CH, reported its latest total carbon emissions for 2025 as approximately 4.36 billion kg CO2e. This includes Scope 1 emissions of 198.4 million kg CO2e, Scope 2 market-based emissions of 15.6 million kg CO2e, and Scope 3 emissions of approximately 4.15 billion kg CO2e. In 2024, total emissions were approximately 4.52 billion kg CO2e, and in 2023, they were approximately 4.87 billion kg CO2e.

Novartis is committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2040. This commitment is supported by Science Based Targets initiative (SBTi) approved targets. For the near term, Novartis aims to reduce absolute Scope 1 and 2 GHG emissions by 90% and absolute Scope 3 GHG emissions by 42% by 2030, both against a 2022 base year. For the long term, Novartis commits to maintaining a minimum of 90% absolute Scope 1 and 2 emissions reductions from 2030 through 2040 from a 2022 base year and to reduce absolute Scope 3 GHG emissions by 90% by 2040 from a 2022 base year. These targets are consistent with keeping global warming to 1.5°C.

Additionally, Novartis aims to become carbon neutral in its own operations (Scope 1 and 2) by 2025 and across its value chain (Scope 1, 2, and 3) by 2030. They have already achieved a 63% reduction in Scope 1 and 2 emissions (from energy) between 2016 and 2023. Novartis also signed The Climate Pledge in 2021, reinforcing its commitment to climate action.